| association id |
FEATURE |
Drug id |
Propr |
Public |
Drug Name |
Drug Target |
N FEATURE pos |
N FEATURE neg |
log max Conc tested |
FEATURE neg logIC50 MEAN |
FEATURE pos logIC50 MEAN |
FEATURE deltaMEAN IC50 |
FEATURE IC50 effectSize |
FEATURE neg Glass delta |
FEATURE pos Glass delta |
ANOVA FEATURE pval |
Tissue ANOVA pval |
MSI ANOVA pval |
ANOVA FEATURE FDR % |
a2 |
BRAF_mut |
1373 |
1 |
1 |
Dabrafenib |
BRAF |
72 |
798 |
2.3 |
3.62 |
-0.659 |
-4.28 |
2.7 ** |
3.1 ** |
1.4 * |
8.8e-45 |
1.26e-81 |
8.3e-02 |
7.3e-38 |
a4 |
BRAF_mut |
1371 |
1 |
1 |
PLX4720 (rescreen) |
BRAF |
81 |
834 |
2.3 |
4.18 |
2.06 |
-2.12 |
2 ** |
2.2 ** |
1.2 * |
1.17e-29 |
3.79e-58 |
1.52e-01 |
4.8e-23 |
a5 |
BRAF_mut |
1036 |
1 |
1 |
PLX4720 |
BRAF |
69 |
776 |
2.3 |
4 |
1.77 |
-2.23 |
1.9 * |
2.1 ** |
1.2 * |
1.01e-22 |
1.18e-45 |
7.04e-01 |
3.3e-16 |
a6 |
BRAF_mut |
1061 |
1 |
1 |
SB590885 |
BRAF |
65 |
761 |
1.61 |
3.78 |
1.81 |
-1.98 |
1.9 * |
2.2 ** |
1 * |
6.35e-18 |
6.21e-44 |
8.74e-01 |
1.7e-11 |
a12 |
BRAF_mut |
1242 |
1 |
1 |
(5Z)-7-Oxozeaenol |
MAP3K7 (TAK1) |
79 |
834 |
2.3 |
0.992 |
-0.879 |
-1.87 |
1.4 * |
1.5 * |
0.98 . |
7.4e-11 |
7.5e-47 |
6.06e-01 |
1e-04 |
a34 |
BRAF_mut |
262 |
1 |
1 |
VX-11e |
ERK |
78 |
841 |
1.63 |
2.88 |
1.61 |
-1.27 |
0.89 . |
0.91 . |
0.73 . |
2.37e-08 |
7.35e-34 |
8.12e-01 |
0.012 |
a46 |
BRAF_mut |
1498 |
1 |
1 |
AZD6244 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
79 |
839 |
1.39 |
1.84 |
-0.371 |
-2.21 |
1.4 * |
1.4 * |
1.1 * |
1.57e-07 |
6.7e-55 |
6.06e-02 |
0.056 |
a82 |
BRAF_mut |
29 |
1 |
1 |
AZ628 |
BRAF |
29 |
374 |
1.39 |
1.84 |
-0.574 |
-2.41 |
1.4 * |
1.5 * |
0.98 . |
4.57e-06 |
1.54e-21 |
1.44e-01 |
0.92 |
a89 |
BRAF_mut |
263 |
1 |
1 |
FR-180204 |
ERK |
78 |
841 |
3 |
4.93 |
4.63 |
-0.302 |
0.34 |
0.35 |
0.33 |
7.29e-06 |
7.62e-37 |
7.83e-01 |
1.3 |
a95 |
BRAF_mut |
1015 |
1 |
1 |
CI-1040 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
70 |
766 |
2.3 |
2.38 |
0.711 |
-1.67 |
1.2 * |
1.2 * |
1.1 * |
8.68e-06 |
1.74e-38 |
2.61e-02 |
1.5 |
a104 |
BRAF_mut |
1526 |
1 |
1 |
RDEA119 (rescreen) |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
75 |
800 |
1.61 |
1.88 |
-0.236 |
-2.12 |
1.3 * |
1.4 * |
1.2 * |
1.56e-05 |
4.38e-62 |
1.68e-01 |
2.5 |
a111 |
BRAF_mut |
295 |
1 |
1 |
NVP-BHG712 |
EPHB4 |
78 |
841 |
2.33 |
3.06 |
2.29 |
-0.77 |
0.47 |
0.46 |
0.53 . |
1.73e-05 |
9.85e-66 |
4.76e-01 |
2.6 |
a125 |
BRAF_mut |
1372 |
1 |
1 |
Trametinib |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
76 |
817 |
0 |
-0.792 |
-3.64 |
-2.85 |
1.2 * |
1.2 * |
1.1 * |
2.21e-05 |
1.91e-62 |
2.18e-01 |
2.9 |
a450 |
BRAF_mut |
1014 |
1 |
1 |
RDEA119 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
67 |
770 |
1.61 |
1.69 |
-0.295 |
-1.99 |
1.1 * |
1.1 * |
1.1 * |
5.77e-04 |
7.95e-51 |
1.05e-01 |
21 |
a527 |
BRAF_mut |
1236 |
1 |
1 |
UNC0638 |
G9a(EHMT2), GLP(EHMT1) |
82 |
846 |
3 |
3.25 |
2.81 |
-0.444 |
0.32 |
0.32 |
0.37 |
7.93e-04 |
2.7e-41 |
4.27e-01 |
25 |
